11 recruiting, 5 active not recruiting, 4 completed, 4 terminated. 19 Phase 2, 11 Phase 1, 3 Not applicable, 1 Phase 3, 1 Phase 4.
Follow Stage III Hepatocellular Carcinoma AJCC v8: new trials by email Literature Review of Stage III Hepatocellular Carcinoma AJCC v8 trials Research Report on Stage III Hepatocellular Carcinoma AJCC v8
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Autologous CAR T Cells Targeting GPC3 (RPCAR01) for the Treatment of Advanced or Metastatic GPC3 Expressing Hepatocellular Carcinoma Anti-GPC3-CAR Autologous T Lymphocytes, Biospecimen Collection, Computed Tomography - Advanced Hepatocellular Carcinoma, Metastatic Hepatocellular Carcinoma | Phase 1 | Suspended | Roswell Park Cancer Institute | 24 | 2026-11-15 | 2026-09-15 |
| Multiple Adjunct Therapies to Improve Immunotherapy Treatment in Patients With Locally Advanced or Metastatic Melanoma or Advanced Hepatocellular Cancer Biospecimen Collection, Cholecalciferol, Computed Tomography - Advanced Hepatocellular Carcinoma, Advanced Melanoma | Phase 2 | Not yet recruiting | University of Southern California | 46 | 2026-11-01 | 2026-09-23 |
| Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tumors, The Knight SHIFT Study Biospecimen Collection, Immune Checkpoint Inhibitor - Advanced Biliary Tract Carcinoma, Advanced Head and Neck Squamous Cell Carcinoma | Phase 4 | Recruiting | OHSU Knight Cancer Institute | 160 | 2026-04-24 | 2026-10-13 |
| Y-90 Radioembolization, Durvalumab, Tremelimumab, and Zanzalintinib for the Treatment of Unresectable and Locally-Advanced Hepatocellular Carcinoma Angiogram, Biopsy Procedure, Biospecimen Collection - Locally Advanced Hepatocellular Carcinoma, Stage III Hepatocellular Carcinoma AJCC v8 | Phase 2 | Not yet recruiting | OHSU Knight Cancer Institute | 40 | 2026-04-02 | 2026-04-06 |
| Zanzalintinib in Second Line and Beyond for the Treatment of Advanced Liver Cancer Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging - Advanced Hepatocellular Carcinoma, Cirrhosis | Phase 1 / Phase 2 | Recruiting | Devalingam Mahalingam | 59 | 2026-03-30 | 2026-10-23 |
| Testing Immunotherapy With or Without Stereotactic Body Radiation Therapy in Patients With Advanced Liver Cancer, HELIO-RT Trial Atezolizumab, Bevacizumab, Biospecimen Collection - Advanced Hepatocellular Carcinoma, Stage III Hepatocellular Carcinoma AJCC v8 | Phase 3 | Recruiting | NRG Oncology | 226 | 2026-02-26 | 2026-08-17 |
| Celecoxib, Durvalumab and Tremelimumab for the Treatment of Patients With Advanced or Metastatic Liver Cancer Celecoxib, Durvalumab, Tremelimumab - Advanced Hepatocellular Carcinoma, Metastatic Hepatocellular Carcinoma | Phase 2 | Recruiting | Emory University | 39 | 2026-01-02 | 2026-01-28 |
| Testing the Addition of an Anti-cancer Drug, Sapanisertib, to the Usual Chemotherapy Treatment (Cabozantinib) in Metastatic Liver Cell Cancer With a Change in Genes for the Protein β-Catenin, The SAPHIRE Trial Biospecimen Collection, Cabozantinib S-malate, Imaging Procedure - Advanced Hepatocellular Carcinoma, Metastatic Hepatocellular Carcinoma | Phase 1 / Phase 2 | Recruiting | National Cancer Institute (NCI) | 92 | 2025-11-17 | 2026-10-26 |
| Y-90 Versus SBRT for Inoperable HCC Quality of Life, Questionnaire Administration, Stereotactic Body Radiation Therapy - Hepatocellular Carcinoma, Stage I Hepatocellular Carcinoma AJCC v8 | Phase 2 | Withdrawn | OHSU Knight Cancer Institute | 2023-12-01 | 2023-03-23 | |
| Regorafenib and Durvalumab for the Treatment of High-Risk Liver Cancer Durvalumab, Regorafenib - Stage IB Hepatocellular Carcinoma AJCC v8, Stage II Hepatocellular Carcinoma AJCC v8 | Phase 2 | Active not recruiting | Academic and Community Cancer Research United | 4 | 2023-07-01 | 2026-07-20 |
| AU409 for the Treatment of Advanced Primary Liver Cancers or Solid Tumor With Liver Metastatic Disease Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging - Advanced Cholangiocarcinoma, Advanced Hepatocellular Carcinoma | Phase 1 | Suspended | University of Southern California | 36 | 2023-03-29 | 2026-08-17 |
| A Phase II Study of Nivolumab + Ipilimumab in Advanced HCC Patients Who Have Progressed on First Line Atezolizumab + Bevacizumab Ipilimumab, Nivolumab - BCLC Stage B Hepatocellular Carcinoma, BCLC Stage C Hepatocellular Carcinoma | Phase 2 | Terminated | Academic and Community Cancer Research United | 15 | 2023-01-19 | 2026-08-04 |
| Atezolizumab in Combination With a Multi-Kinase Inhibitor for the Treatment of Unresectable, Locally Advanced, or Metastatic Liver Cancer Atezolizumab, Cabozantinib, Lenvatinib - Locally Advanced Hepatocellular Carcinoma, Metastatic Hepatocellular Carcinoma | Phase 2 | Recruiting | Academic and Community Cancer Research United | 122 | 2022-05-27 | 2026-08-04 |
| Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or Thorax Atezolizumab, Cabozantinib S-malate, Nab-paclitaxel - Advanced Breast Carcinoma, Advanced Endometrial Carcinoma | Phase 1 | Recruiting | M.D. Anderson Cancer Center | 43 | 2022-04-29 | 2026-07-16 |
| Lenvatinib for the Treatment of Recurrent Hepatocellular Carcinoma After Liver Transplant Laboratory Biomarker Analysis, Lenvatinib - Recurrent Hepatocellular Carcinoma, Stage III Hepatocellular Carcinoma AJCC v8 | Phase 2 | Terminated | Emory University | 3 | 2022-04-19 | 2026-04-24 |
| Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors Cyclophosphamide, Neoantigen Peptide Vaccine, Pembrolizumab - Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8 | Phase 1 / Phase 2 | Recruiting | Mayo Clinic | 138 | 2022-03-31 | 2026-08-20 |
| Durvalumab With/Without Tremelimumab After Palliative Hypofractionated Radiotherapy for Hepatocellular Carcinoma Durvalumab, Hypofractionated Radiation Therapy, Tremelimumab - Advanced Hepatocellular Carcinoma, Stage III Hepatocellular Carcinoma AJCC v8 | Phase 2 | Recruiting | Mary Feng, MD | 21 | 2022-02-04 | 2025-12-08 |
| 68Ga PSMA PET Imaging for the Treatment of Advanced Liver Cancer Computed Tomography, Gallium Ga 68 Gozetotide, Positron Emission Tomography - Advanced Hepatocellular Carcinoma, Stage III Hepatocellular Carcinoma AJCC v8 | Phase 2 | Completed | Mayo Clinic | 26 | 2022-01-30 | 2026-09-29 |
| Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV Biospecimen Collection, Cabozantinib S-malate, Computed Tomography - Advanced Differentiated Thyroid Gland Carcinoma, Advanced Head and Neck Carcinoma | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 8 | 2021-11-22 | 2026-05-28 |
| Stereotactic Body Proton Radiotherapy for the Treatment of Liver Cancer Proton Stereotactic Body Radiation Therapy, Quality-of-Life Assessment - Recurrent Hepatocellular Carcinoma, Stage I Hepatocellular Carcinoma AJCC v8 | Phase 2 | Terminated | Mayo Clinic | 9 | 2021-08-24 | 2025-12-31 |
Showing 20 of 29. Sign in to see all of them.
Carcinoma, Hepatocellular (29) · Carcinoma, Renal Cell (4) · Melanoma (4) · Carcinoma, Non-Small-Cell Lung (3) · Lung Neoplasms (3) · Neoplasm Metastasis (3) · Carcinoma, Transitional Cell (2) · Cholangiocarcinoma (2) · Endometrial Neoplasms (2) · Ovarian Neoplasms (2) · Squamous Cell Carcinoma of Head and Neck (2) · Triple Negative Breast Neoplasms (2) · Breast Neoplasms (1) · Carcinoma, Lobular (1) · Carcinoma, Medullary (1)
Adenocarcinoma (29) · Carcinoma (29) · Digestive System Diseases (29) · Digestive System Neoplasms (29) · Liver Diseases (29) · Liver Neoplasms (29) · Neoplasms (29) · Neoplasms by Histologic Type (29) · Neoplasms by Site (29) · Neoplasms, Glandular and Epithelial (29) · Skin Diseases (5) · Skin and Connective Tissue Diseases (5) · Female Urogenital Diseases (4) · Female Urogenital Diseases and Pregnancy Complications (4) · Kidney Diseases (4)
Magnetic Resonance Spectroscopy (12) · Specimen Handling (12) · Immunoglobulin G (8) · Disulfides (7) · durvalumab (7) · Nivolumab (6) · tremelimumab (5) · Biopsy (4) · X-Rays (4) · atezolizumab (4) · cabozantinib (4) · Bevacizumab (2) · CTLA-4 Antigen (2) · Cyclophosphamide (2) · Ipilimumab (2)
M.D. Anderson Cancer Center (5) · Mayo Clinic (4) · Academic and Community Cancer Research United (3) · National Cancer Institute (NCI) (3) · OHSU Knight Cancer Institute (3) · Emory University (2) · University of Southern California (2) · City of Hope Medical Center (1) · Devalingam Mahalingam (1) · Edward Kim (1) · Mary Feng, MD (1) · NRG Oncology (1) · Robin Kate Kelley (1) · Roswell Park Cancer Institute (1)
United States (28) · Canada (1)
Armeen Mahvash (2) · Mehmet Akce (2) · Adel Kardosh (1) · Anthony B El-Khoueiry, MD (1) · Anuradha Krishnamurthy (1) · Anwaar Saeed (1) · Apostolia M Tsimberidou (1) · Daneng Li (1) · Devalingam Mahalingam (1) · Diana Hanna (1) · Dustin A Deming (1) · Edward Kim, MD, PhD (1) · Haiying Cheng (1) · Jennifer Y Wo (1) · Jonathan B. Ashman, M.D., Ph.D. (1)
PMID 34272087, PMID 39932259, PMID 41831609, PMID 42847673
P30CA015083 (3), P30CA014089 (2), P30CA016672 (2), P30CA138292 (2), P30CA033572 (1), P30CA060553 (1), P30CA093373 (1), R01CA274985 (1), R01CA294704 (1), U10CA180820 (1), U10CA180868 (1), UM1CA186690 (1)